• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention relates to new compounds, salts, complexes and acylated derivatives thereof, methods of producing said compounds, intermediates used in the method, pharmaceutical compositions containing the present compounds and methods of producing same, and a method of treating patients using the present compounds, having the general formula (I) <IMAGE> I in which R1 represents hydrogen, alkyl, alkoxy, hydroxy, halogen, trifluoromethyl, or phenyl; R2 represents hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, or hydroxy; R3 represents alkyl, cycloalkyl which can be further mono- or disubstituted with methyl or ethyl, phenyl or phenyl-alkyl, optionally being further substituted; and R4 represents a 5- or 6-membered heterocyclic ring system containing at least one nitrogen atom and optionally further nitrogen, oxygen and/or sulphur atoms, said ring system optionally being further substituted; or said ring system optionally forming part of a larger fused ring system; and pharmaceutically acceptable, non-toxic salts, complexes and acylated derivatives thereof. The present compounds can be used in the therapy of rheumatoid arthritis, osteo-arthritis, and allied conditions in humans and domestic animals by enteral, parenteral or topical administration.
    公开号:SU828967A3
    申请号:SU782685598
    申请日:1978-11-04
    公开日:1981-05-07
    发明作者:Раклин Шноер；Арригони-Мартелли Эдоардо
    申请人:Лео Фармасьютикал Продактс Лтд,A/C (Левенс Кемиске Фабрик Продук-Ционсактиесельскаб) (Фирма)；
    IPC主号:
    专利说明:

    (54) THE METHOD OF OBTAINING GUANIDINE DERIVATIVES OR THEIR ACID-ADDITIVE SALTS OR THEIR COMPLEXES WITH ORGANIZABLE HEADS OF THE METALS OF THE METALS Koiropibril 4 is (2-l-glyceroxycloxy) and has a 4% (2-l-glyceroxycloxy) sugar content that is aceto-4- (2-l-glyceroxy-oxyfes); acid. This compound has biologically active properties. The purpose of the invention is to obtain new compounds expanding the arsenal of means of influencing a living organism. This goal is achieved by the method of obtaining compounds of the formula T or their acid addition salts, or their complexes with inorganic metal pains, which is that the carbodiimide of the general formula in) is reacted with an amine of the general formula Rg-NHj where R ,, RJ and Rg are different and one of them means the radical of the general formula where R and Rj have the indicated values, the other is R, the third is R, the temperature is from room temperature to 120 ° C, if necessary in the presence of an inert solvent, from 30 minutes to 24 h and the selection of the target product in its A form of sludge in the form of acid addition salts yl complexed with an inorganic salt or metal-title product, where Ry - hydrogen atom, converted to the desired product, where R - acetyl acylation. The reaction is preferably carried out in the presence of an inert solvent, for example diethyl ether. In addition, the reaction can be carried out without solvent; in this case, the resulting compound of formula I is isolated by triturating the reaction mixture, for example, with diethyl or petroleum ether. Compounds of formula T are preferably purified by recrystallization from appropriate solvents, for example cyclohexane, diethyl ether; cyclohexanol, petroleum ether, isopropanol, or a mixture of solvent, for example acetone-water or ethanol-water; however, other methods of purification can be used. Salts of compounds of the formula | they can be neutralized by combining the scientific research institute with an acid in a reaction medium that facilitates the reaction, from which the salt can either precipitate φ, or, if necessary, can be precipitated by adding an appropriate component to decrease its solubility, or it can be isolated by evaporation of the reaction mixture. In addition, in some cases, the oly can be obtained directly by reacting the corresponding amine salt with the carbodimide or the salt of the compound of formula J previously prepared can be reacted with an acid, or the solid salt of the compound of formula j can be obtained by double exchange of the previously prepared salt Compound of formula i with another salt containing the desired anion or with an acid. Mono- or double salts are obtained depending on the ratio between the reagents forming the salt. Example. M-Cyclohexyl-c-4- {2-methylquinolyl) -M-2-thiazolylguanidine (5R 1368). A. M-Cyclohexyl-M-4- (2-methylquonolyl) -carbodiimide. A mixture consisting of N-cyclohexyl-N-4- (2-methylquinolyl) urea (283.0 g), triethylamine (75 ml), carbon tetrachloride (50 ml), triphenylphosphine (150 g) in a solution of dry methylene chloride (1.0 L), refluxed for 2 hours with overpowering. The mixture is then concentrated in vacuo. The residue is extracted with four portions of boiling petroleum ether (b.p. below 50 ° C) (2.0 L). The combined extracts were evaporated in vacuo to give crude carbodiimide in high yield. IR spectrum (s): strong absorption band at 2140 cm (N). B. M-Cyclohexyl-4- (2-methylquinolyl) -2-thiaisolylguanidine. 2-Aminothiazole (73.0 g) was added to crude M-cyclohexyl-n-4- (2-methylquinolyl) -carbodiimide (209.0 g), the mixture was heated on the steam bath for 1 hour and allowed to cool to room temperature. temperature The mixture is then triturated with 400 ml of ethyl acetate. The crystalline precipitate is collected and recrystallized from 1-propanol; m.p. its 194-195 ° C. The free base in the form of a solution of ethanol is converted into hydrochloride by treating it with an equivalent amount of a solution of 1 mol of hydrogen chloride in ethanol; m.p. monohydrochloride 236-237s. When using an excess of hydrogen chloride in ethanol, dihydrochloride is obtained, so pl. 234-235 C. Zinc complex is obtained by adding a solution of anhydrous ZnCl2 (g) in 10.0 ml of absolute ethanol to a solution of 2.0 g of SR 1368 hydrochloride in 20 ml of absolute ethanol. The precipitated complex is filtered off and an analytically pure compound is obtained, mp.
    247-249 ° C; CJQ Hjj NA 1 ZnC Ig (white crystals).
    The following complexes are similar to crawlers: CoC 23% S “HC I, so pl. 152-154 ° C (blue crystals); SSC-CjoH -jNffS-HCl, t. Pl. 174IVe C (brown crystals); 1/2 MpSCN O-Sgo H2iNj-S, so pl. 215-217c {white crystals),
    NMR spectrum of the title compound {10% (by weight) solution in - (
     n multipleg 0.9-2
    -CHj-CHf
    m
    ten
    15
    1H
    4H
    7.18
    7.2-8.2 30
    Examples 2-16. Following the procedure described in Example 1, but replacing 2-aminothiazole with other amines of the formula RgNH, where 35 Cd has the meanings given in table. 1, obtain the corresponding guanidine derivatives of the general formula
    40
    K C -TJH- / N
    which are presented in this table.
    Table
    III
    180-182
    H,
    to
    HJ
    180-182 n.
    liT
    5 (J200 (
    170-172
    45
    .eleven
    Example 17. M-tert.-Butyl-M-4- (-methylquinolyl) -N -2-thiazolylguanidine.
    2-Aminothiazole (1.0 g) is added to the crude N-tert-butyl-m-4- (2-methylquinolyl) -carbodime (2.8 g). The mixture is heated on a steam bath for 15 minutes and left
    cool to room temperature. After 12 h, the mixture is dispensed into a powder with 25 ml of diethyl ether. The resulting crystalline precipitate is collected; it is analytically pure,
    tpl .. its 194-19bs,
    NMR spectrum 10% solution in the U singlet Examples 18-28. The following is the method described in Example 17, but for 2-aminothiazole, other amines of the formula RgNH, where R has the meanings given in the table, the corresponding guanidine derivatives of the general formula w are obtained (i-wH-c-CH, 1 i HR4 JH3)
    The continuation of the table.2. Example 29. N-Ethyl-M-L- (2-methylquinolyl) -N -2-thiazolyl guanide {1H. Following the procedure of Example 1, but replacing M-cyclohexyl-c-4- (2-methyl-quinolyl) -carbodiimide with M-ethyl-m-4- (2-methyl-quinolyl.) -Carbodiimide, the title compound is obtained, mp . 183-185-s (after crystallization from ethyl acetate, NMR spectrum (10% solution in SOSTS) 5 ON triplet 1 7 1.25 CH din (i 2Hm CH -CHj. HY-YH,
    Jf-vCH,
    oj
    3 H 7.0-8.2 P p And M e ry 33-56. Following the procedure of Example 1, but replacing the N-cyclo-60 rej: cHn-N -4- (2-methylquinolyl) -carbodiimide with the corresponding carbodiimide, where R is 2-methyl, Rji. the values given in table. 3, the corresponding derivatives are obtained: 65
    82896710
    guanidine general formula
    2.75
    183-185 pentyl 131-132 45 Cyclohexylmethyl (dinitrate) 170-171 464-Methylcyclohexyl 166-167 472,3-Dimethylcyclo (hydrochloride) hexyl 167-169 48 Cycloheptyl
    Continued table. 3
    Continuation of table.4.
    Examples 64-73. Following the procedure of Example 1, but replacing the N-cyclohexyl-M-4- (2-methylquinolyl) -car 5 bodyimide with the corresponding carbolimides, where R and Rj are as shown in Table. 5, the corresponding guanidine derivatives of the general formula are obtained. Example 57. N-Cyclohexyl-N-4- {2-methylquinolyl) -2- (L-thiazolyl) -guanidine. Following the procedure of Example 1, but replacing 2-aminothiazole with 2-amino-d-azoline, the title compound is obtained, mp. 129-131 C (after recrystallization from diethyl ether). Examples 58-63. Following the procedure of Example 57, but replacing N-cyclohexyl-m-4- (2-methylquinolyl) -carbodiimide with the corresponding carbium dyes, where R is 2-methyl, R 2 H and R has the table. 4 values obtain the corresponding guanidine derivatives of the general formula -T (H- / in Table 5. Table 5
    45
    50
    which are presented in table. four,
    Ta b faces 4
    60
    Examples 74-77. Following the procedure of Example 31, but replacing 4-amino-2-methyl nickeline with amines, in which R and Rg have the values given in Table 6 of 65, the corresponding 138289 guanidine derivatives of the general formula, Jf p. K 4J-Hli-i-Hj CNSN, which are presented in Table. 6. T a b p ii c a 6
    2-ce
    75
    79
    Example 88. N-Cyclohexyl-4- (2-methylquinolyl) (1,2,4-triazinyl) -guanidine.
    Following the procedure described in Example 1, but replacing 2-aminothiazole with 3-amino-1,2,4-triazine, the title compound is obtained.
    Example 89. N-Cyclohexyl-N -4- (2-methylquinolyl) -m -2- (1,3,5-t azazinyl) -guanidine.
    Following the procedure described in Example 1, but replacing 2-aminothiazral with 2-amino-1,3,5-triazine, the title compound is obtained .. 10
    (; H5-J-CH-108-110
    Example 90. M-Acetyl-M-Cyclohexyl-M-4- (2-methylquinolyl) -M-2-thiazolylguanidine.
    A. 2-Acetamidothiazole (1.4 g) is stirred in dry dimethylformamide (10 ml) and 0.5 g of NaH (50% dispersion in mineral oil) is added and then M-cyclohexyl-4- (2- methylquinolyl) -carbodiimide (2.7 g). The mixture is stirred for 4 hours at room temperature and packed in a vacuum. After grinding the residue into petroleum ether
    15 ml of water are added, and 7 14 continued. Table 6. P r. And measures 78-87. Following the procedure of Example 17, but replacing N-tert.-butyl-M-4- (2-methylquinolyl) -carbodiimide with the corresponding carbodiimides, in which R, Rj and R have the meanings given in table. 7, the corresponding guanidine derivatives of the general formula are obtained with a pH of up to 7.0 by adding KH2PO4 (1.5 g in 10 ml of water and diluted with 2N ammonium hydroxide solution. The precipitate is filtered and dried; melt it ISL-SS C.B. The title compound is also obtained by mixing H with cyclohexyl-n-4- (2-methylquinolyl) -H-2-thiazolylguanidine (32 g) with acetic anhydride {220 1 ml. After stirring for 10 minutes, a clear solution is obtained, which after stirring with at room temperature for 20 hours gradually hardens. they are collected, washed with ethyl acetate, water, acetone and ether; T..PL is 158-1 ° C °. Example 91. N-Cyclohexyl-N-4- (2-methylquinolyl) -N-propionyl-N-2-thiazolylguanidine , dihydrate. Following the procedure of Example 90A, but replacing 2-acetamidothiazole with 2-propionamidothiazole, the title compound is obtained, mp 140142 ° C. Example 92, H-Acetyl-Y-tert, -butyl-N-4 - (2-methylquinolyl) -N-2-thiazolylguanidine. Following the procedure of Example 90B. but replacing M-cyclohexyl-m-4- (2-methyl quinolyl) -M -2-thiazolylguanidine with N-tert.-butyl-n -4- (2-methylquinolyl) -N-2-thiazolylguanidine, the title compound is obtained t. pl. 150-152 ° C. The compounds of the formula T are potential anti-inflammatory, analgesic and anti-inflammatory agents with low acute toxicity and low stomach withdrawing ability. These compounds are bases and form mono- or double salts with acids, among which nontoxic, pharmaceutically acceptable salts of hydrochloric acid and hydrobromic acid, phosphoric, sulfuric, nitric, carbonic acid, p-toluenesulfonic acid, methanesulfonic acid, and formic acid can be noted. , acetic, propionic, citric, basal and maleic acids. The compounds of formula jf and their salts, in addition, form complexes with certain metal salts, for example, with salts of copper in zinc, manganese, magnesium, iron and gold. Salts and complexes are also biologically active. The proposed compounds can be used in the treatment of rheumatoid arthritis, osteoarthritis and related diseases of humans and domestic animals by enteral parenteral or local application. In experiments with animals, compounds of the formula (showed high therapeutic effect. For example, compound of Example 1 (SR 1368 can be compared with indometaine, one of the most widely used and most active anti-inflammatory drugs. results; 1C Acute toxicity. Acute toxicity was determined in mice after oral administration. Mortality of mice was evaluated eight days after administration and the value of 10.5 d was calculated (lethal dose causing 50% mortality of test animals) according to a statistical method. Litchchild and Wilcoxon. The results are shown in Table 8. T a b litsa {SR 1368, Indomethacin 23 (16-32) 2. Inhibition of carrageenan edema. Inhibiting activity against carpenin-induced edema was evaluated in rats using the method Iku Winter To, And. and others. Compounds were administered orally, as a suspension in 0.5% carboxymethylcellulose to starving animals for 18 hours, 1 hour before the injection of carrageenan. The results, expressed as a percentage of inhibition of the development of edema in the test animals compared with the control, are given in Table. 9. Table 9
    3. Inhibition of arthritis caused by a stimulant.
    Stimulated arthritis was induced in rats according to the Walz method, dt, et al. Compounds suspended in O, 5% carboxymethylcellulose were orally administered daily from the day
    The results show an increase in the 6-salt threshold, which is observed 2 hours after oral administration of the compounds.
    Table 12
    stimulator injections for 28 days. Given in Table. 10 results show the percent inhibition of primary as well as secondary swelling, which was assessed compared to control 18 and 28 days after the injection of the stimulator.
    Table 10
    7. Ingest stomach activity.
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining guanidine derivatives of the general formula where is a hydrogen atom, a Cf-C ^ -alkyl, a C ^ -C ^ -alkoxy group, an oxy group, a halogen atom, trifluoromethyl or phenyl;
    Rg is a hydrogen atom, a C ^ -C ^ -alkyl, a C.4-C ^ -alkoxy group, a halogen atom, trifluoromethyl or hydroxy group;
    - C ^ ~ C f g-alkyl or Cj-Cg-cycloalkyl, which may be 5 additionally mono- or disubstituted by methyl or ethyl, phenyl or C ^ -Cd -'alkylphenyl, which may be further substituted by methyl, methoxy, atom
    15 halogen or trifluoromethyl;
    - thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, isoxazolyl, triazolyl, benzimidazolyl, pyridyl, thye2Q nyl, pyrazinyl or thiazolinyl, the radical R ^ optionally being substituted with one or two methyls or carboxy, carbethoxy group or mercapt;
    'R 5 - a hydrogen atom or acetyl, or their acid additive salts, or their complexes with inorganic metal salts, characterized in that the carbodiimide of the General formula
    B 6 W = C-NR 7 (ϊ) is reacted with an amine of the general formula r 8 ~ nh 2 where R ^, R 7 and Rg are different and one of them means a radical of the general formula i
    where R and Rg have the above meanings, the other is the third; R ^, when
    45 temperature from room temperature to 120 ° С, if necessary in the presence of an inert solvent, for a period of time from 30 minutes to 24 hours and the desired product is isolated in a free 50 form or in the form of an acid additive. salt, or in the form of a complex with an inorganic metal salt or the target product, where R - a hydrogen atom, is transferred to the target product,
    55 where is acetyl by acylation.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU828967A3|1981-05-07|Method of preparing guanidine derivatives or their acid-additive salts or their complexes with inorganic metal salts
    IE54667B1|1990-01-03|Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them
    US4501745A|1985-02-26|Anxiolytic imidazo[1,2-a]pyridine derivatives
    HU210822A9|1995-08-28|Pyrimidine-4,6-dicarboxylic acid diamides, processes for the use thereof, and pharmaceuticals based on these compounds
    US4112234A|1978-09-05|Imidazolylmethylthioethyl alkynyl guanidines
    GB2177089A|1987-01-14|Thiazolidinecarboxylic acid derivatives
    IE59141B1|1994-01-12|N-substituted 2-amino-thiazoles, process for their preparation and their therapeutic application
    US4904659A|1990-02-27|Substituted quinoline derivatives and pharmaceutical compositions thereof
    US4691018A|1987-09-01|Pyridine derivatives and their use as anti-allergic agents
    EP1142885A1|2001-10-10|Novel 2-|thiazolidin-4-one derivatives
    US4725598A|1988-02-16|Derivative of dihydroxybenzamide and a pharmaceutical composition having an anti-inflammatory activity
    DE2461802A1|1975-07-17|PYRAZINE DERIVATIVES
    US4404214A|1983-09-13|2-Pyridinecarboxamide derivatives compositions containing same and method of using same
    KR900004828B1|1990-07-07|Process for the preparation of phenylnaphthyridine
    FR2567887A1|1986-01-24|NEW SUBSTITUTED AMIDES, THEIR PREPARATION AND THE MEDICINES THAT CONTAIN THEM
    US4157347A|1979-06-05|N-cyano isothioureas
    US4072679A|1978-02-07|1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO |-benzimidazole-3-carboxylic acids, esters and amides
    CA1110251A|1981-10-06|N-cyano-n&#39;- 2-¬|methylthio|ethyl - n&#34;-alkynylguanidines h.sub.2 receptor blocking agents
    US4520131A|1985-05-28|Antihypertensive N-substituted 1,4-dihydropyridines
    IL45995A|1977-06-30|4-pyridylthiazole-2-carboxamides and acetamides their preparation and pharmaceutical compositions containing them
    US3378564A|1968-04-16|Certain pyridyl tetrazole derivatives
    US4500532A|1985-02-19|1-|-1,4-dihydropyridines
    US3673177A|1972-06-27|Substituted 4-|-3-galanthamaninones
    US5663181A|1997-09-02|Naphthyridine derivatives, their methods of preparation and pharmaceutical compositions in which they are present, useful especially as antiproliferative drugs
    US4038283A|1977-07-26|4-Alkoxy or hydroxy derivatives of 2H-pyrazolo[3,4-b]pyridine-5-carboxylic acids and esters
    同族专利:
    公开号 | 公开日
    FR2407930A1|1979-06-01|
    IE782084L|1979-05-07|
    NL7811035A|1979-05-09|
    LU80476A1|1979-06-15|
    AU517670B2|1981-08-20|
    JPS5473784A|1979-06-13|
    ATA773278A|1981-08-15|
    DK493378A|1979-05-08|
    PH16296A|1983-09-05|
    FI69463C|1986-02-10|
    ZA786175B|1979-10-31|
    IT7829514D0|1978-11-07|
    FI69463B|1985-10-31|
    FI783327A|1979-05-08|
    DK153950B|1988-09-26|
    US4293549A|1981-10-06|
    FR2407930B1|1983-03-18|
    YU257578A|1983-01-21|
    PT68750A|1978-12-01|
    IE47458B1|1984-03-21|
    IT1100075B|1985-09-28|
    YU41129B|1986-12-31|
    NZ188770A|1984-07-31|
    DE2847792C2|1988-02-04|
    BE871807A|1979-05-07|
    ES474900A1|1980-04-16|
    CA1120929A|1982-03-30|
    SE7811457L|1979-05-08|
    GR65010B|1980-06-12|
    AT366368B|1982-04-13|
    SE446267B|1986-08-25|
    AU4137678A|1979-05-17|
    CH645354A5|1984-09-28|
    DE2847792A1|1979-05-10|
    JPS6348873B2|1988-09-30|
    DK153950C|1989-02-20|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR353M|1957-05-07|Ciba Geigy|New quinoline usable in therapy.|
    GB889262A|1959-07-03|1962-02-14|Ciba Ltd|Quinoline compounds|
    US3159676A|1962-02-07|1964-12-01|Smith Kline French Lab|Naphthyl containing guanidines|
    US3852293A|1972-06-21|1974-12-03|Uniroyal Inc|4-phenyl-2--thiazole carboxamides|
    US4000279A|1974-10-29|1976-12-28|Armour Pharmaceutical Company|Pharmaceutical preparations containing 5'-guanidine compounds and methods of using same|US6306846B1|1972-05-31|2001-10-23|John R. J. Sorenson|Anti-inflammatory and anti-ulcer compounds and process|
    IT1205640B|1983-04-06|1989-03-23|Yason Srl|NEW COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM|
    US4563460A|1984-01-13|1986-01-07|William H. Rorer, Inc.|Quinoline and quinazoline derivatives for treating gastrointestinal motility dysfunctions|
    HU195487B|1985-06-04|1988-05-30|Egyt Gyogyszervegyeszeti Gyar|Process for producing quinoline derivatives|
    ES2031514T3|1986-08-29|1992-12-16|Pfizer Inc.|2-GUANIDINO-4-ARILTIAZOLES FOR THE TREATMENT OF PEPTIC ULCERS.|
    US6100260A|1997-04-21|2000-08-08|Sumitomo Pharmaceutical Company, Limited|Isoxazole derivatives|
    EP0928793B1|1998-01-02|2002-05-15|F. Hoffmann-La Roche Ag|Thiazole derivatives|
    NZ507760A|1998-03-26|2002-10-25|Japan Tobacco Inc|Amide derivatives and nociceptin antagonists|
    WO2001032604A1|1999-11-05|2001-05-10|University College London|Activators of soluble guanylate cyclase|
    US7186725B2|2003-01-03|2007-03-06|Genzyme Corporation|Anti-inflammatory compositions and methods|
    WO2004064730A2|2003-01-14|2004-08-05|Cytokinetics, Inc.|Compounds, compositions and methods|
    GB0404434D0|2004-02-27|2004-03-31|Novartis Ag|Organic compounds|
    EP1917244A2|2005-08-24|2008-05-07|Abbott GmbH & Co. KG|Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB4616677|1977-11-07|
    [返回顶部]